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Abstract
Growing evidence from rodent models of temporal lobe epilepsy (TLE) indicates that dysregulation of the mammalian
target of rapamycin (mTOR) pathway is involved in seizures and epileptogenesis. However, the role of the mTOR pathway in
the epileptogenic process remains poorly understood. Here, we used an animal model of TLE and sclerotic hippocampus
from patients with refractory TLE to determine whether cell-type specific activation of mTOR signaling occurs during each
stage of epileptogenesis. In the TLE mouse model, we found that hyperactivation of the mTOR pathway is present in distinct
hippocampal subfields at three different stages after kainate-induced seizures, and occurs in neurons of the granular and
pyramidal cell layers, in reactive astrocytes, and in dispersed granule cells, respectively. In agreement with the findings in
TLE mice, upregulated mTOR was observed in the sclerotic hippocampus of TLE patients. All sclerotic hippocampus (n=13)
exhibited widespread reactive astrocytes with overactivated mTOR, some of which invaded the dispersed granular layer.
Moreover, two sclerotic hippocampus exhibited mTOR activation in some of the granule cells, which was accompanied by
cell body hypertrophy. Taken together, our results indicate that mTOR activation is most prominent in reactive astrocytes in
both an animal model of TLE and the sclerotic hippocampus from patients with drug resistant TLE.
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Introduction
Temporal lobe epilepsy (TLE) is the most common form of
epilepsy in adults, and mesial TLE (mTLE) is often medically
intractable [1–3]. The majority (approximately 80%) of mTLE
patients have seizures that cannot be well controlled with classical
anticonvulsant drugs that target ion channels, suggesting that the
pathogenesis of mTLE differs from other types of epilepsy [4].
Thus, there is a pressing need to develop new and effective drugs
based on our understanding of the molecular mechanisms
underlying the epileptogenic process. Many researchers are
shifting their focus from membrane proteins to intracellular
molecules to find disturbances in signal transduction that may
contribute to abnormal neural network activity in TLE [5]. In
addition, a number of studies demonstrated that a key role of
astrocytes in seizure activity was to drive neurons to seizure
threshold [6,7], and to generate deficits in neuronal inhibition
[8,9]. These findings suggest several novel astrocyte-related targets
for drug development.
The mTOR (mammalian target of rapamycin) signaling
pathway integrates both intracellular and extracellular signals
and serves as a hub regulator of cell growth, proliferation, survival,
differentiation, and homeostasis [10,11]. In the nervous system,
mTOR plays important roles in neuronal development, neurite
outgrowth and synaptic plasticity [12,13]. Dysregulation of
mTOR signaling has been implicated in various neuropathological
disorders including cortical dysplasia, tuberous sclerosis, and
neurodegenerative disorders such as Alzheimer’s disease [14].
Recent studies using rodent models of TLE provide evidence
that overactivation of the mTOR pathway may contribute to
epileptogenesis and spontaneous epileptiform discharges [15,16].
The first suggestion that mTOR could be a potential therapeutic
target for epilepsy came from studies using a mouse model of
tuberous sclerosis complex. In these mice, early treatment with
rapamycin to inhibit mTOR activation prevents development of
epilepsy, and later rapamycin treatment in mice that have already
developed epilepsy suppresses seizures [17]. In rodent models of
TLE, mTOR is overactivated in hippocampus by chemically-
induced seizures, and rapamycin treatment reduces mossy fiber
sprouting [18,19] and inhibits epileptic seizures [20]. Furthermore,
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e39152a ketogenic diet may be an effective treatment for refractory
epilepsy because it inhibits the mTOR pathway [21].
The epileptogenic process involves many pathological changes
at the cellular and molecular levels [22,23], and mTOR pathway
is involved in temporal lobe epileptogenesis. Thus, gaining insight
into the spatio-temporal pattern of mTOR activation during the
onset and progression of epilepsy will increase our understanding
of the potential anti-epileptogenic role of mTOR inhibitors. This
study aimed to investigate the expression and cellular distribution
of phosphorylated S6 ribosomal protein(pS6) on ser235/236, a site
well known to be selectively phosphorylated by mTOR and widely
used to monitor mTOR activation [11,24,25], in both a kainate-
induced TLE mouse model and surgical specimens from patients
with intractable mTLE.
Methods
Ethics Statement
All patients gave written informed consent prior to participation
and all procedures in this study were approved by the Ethics
Committee of Chinese Academy of Medical Sciences, Peking
Union Medical College, and the ethics committee of the Peking
Union Medical College Hospital (PUMCH).
All animal work was approved by the Experimental Animal
Center of Peking Union Medical College and in accordance with
the institutional guidelines of the Beijing Administration Office of
Laboratory Animals. All efforts were made to minimize animal
suffering and reduce the number of animals used.
Tissues from Patients with Refractory mTLE and Non-
sclerotic Controls
Surgically resected sclerotic hippocampi used in this study
were obtained from 18 patients with intractable TLE who
underwent surgical treatment at PUMCH. Thirteen patients
were diagnosed with hippocampal sclerosis (HS) according to
magnetic resonance imaging measurements, electroencephalo-
graohic studies, and histopathologic examination. In the other
five patients, focal lesions such as gliomas, cortical dysplasias or
oligodendroglioma was observed, but did not involve the
hippocampus, and histological examination revealed no signif-
icant hippocampal neuronal loss in these patients (non-HS). The
non-HS subjects were used as a control group for comparison
with the HS cases, similarly to previous studies [26–29]. Table 1
summarizes the clinical features of the TLE-HS and non-HS
subjects.
Surgically resected tissues were immediately stored below 10
degrees Celsius and treated with 10% buffered formalin within 1 h
after surgery, fixed no later than 48 h, and then embedded in
paraffin. Paraffin-embedded tissues were sectioned at 4 mm for
immunohistochemistry studies.
Experimental Animals and Kainic Acid (KA) Induced
Mouse Model of TLE
We used adult male C57BL/6 mice (Vital River Animal
Technology Co., Ltd., Beijing, China) weighing 20–24 g. For
induction of status epilepticus (SE), mice were first anesthetized
and stereotaxically injected with 200 ng KA (Sigma, Shanghai,
China) in 0.05 ml saline into the right dorsal hippocampus
(anteroposterior (AP) =22.0, mediolateral (ML) =21.8, dorso-
ventral (DV) =22.3 mm), using standard methods [30,31]. We
selected three time points after the KA injection (6 h, 5 days, and 5
weeks) to represent the different stages of epileptogenesis [32].
These time points were also examined in a previous study on
mTOR activation in TLE [20]. At least four KA-injected mice
were sacrificed at each time point for immunohistochemical
evaluation. Control mice were injected with saline alone prior to
sacrifice.
Immunohistochemistry Analysis
KA injected and control mice were deeply anesthetized with
pentobarbital, and their brains were rapidly removed, washed
with PBS, incubated for at least 48 h in 4% paraformaldehyde
(Sigma, ShangHai, China) and paraffin embedded. Paraffin-
embedded tissues were sectioned at 4 mm and, mounted on
precoated glass slides (GoldenBridge, Beijing, China). Sections
with hippocampal structure were used for immunohistochemistry
or immunofluorescence studies. The following primary antibodies
were used: phospho-S6 ribosomal protein (Ser235/236) antibody
(1:800 in mouse section, 1:200 in human sections, Cell Signaling
Technologies, American, #2211), anti-NeuN (1:100; Millipore,
American, #MAB377), and anti-glial fibrillary acidic protein
(GFAP) (1:500; Abcam, American, #ab4674). Immunohisto-
chemistry was performed using standard methods. After incu-
bating with primary antibody at 4uC overnight, tissue was treated
with polymer helper and poly peroxidase-anti-goat IgG (Gold-
enBridge, Beijing, China) for 10 min each and subsequently
incubated in DAB (GoldenBridge, Beijing, China) for the
appropriate time. Counterstaining was done with hematoxylin
(GoldenBridge, Beijing, China). After each incubation step,
sections were washed with TBST (365 min).
For immunofluorescence assays, after incubation with the mixed
primary antibodies, the slices were incubated with an anti-rabbit
secondary antibody conjugated with Alexa488 and Alexa555
(1:500; Molecular Probes, American) to detect pS6 and GFAP.
DAPI (Molecular Probes) was used as a nuclear counterstain. All
images were captured using an Axioskop fluorescence microscope
(Zeiss, Germany).
Measurement of Cell Number, Size and Statistical
Analysis
After immunofluorescence or immunohistochemistry staining,
cell counts were performed on acquired images, by counting cells
stained with pS6, GFAP, Neun, pS6/GFAP or pS6/NeuN double-
labeled cells. For each mouse or human hippocampus, we
analyzed four sections chosen at different levels of anteriority. As
shown in Fig. 1, we counted pS6 positive neurons and the numbers
of neuron in DG, CA1, CA3, respectively, and calculated the
percentage in each of the 3 selected regions. As shown in Fig. 2,
GFAP positive and pS6/GFAP double-positive cells were counted
in an area of 650 mm x 900 mm in the CA1 subfield. As shown in
Fig. 3, we calculated the numbers of astrocyte-like pS6 positive
cells in a region shown in Fig. 3D a–h (14400 mm
2). For each
section of human hippocampus, three different areas in each of the
4 selected regions were analyzed (molecular layer of DG, hilus,
CA3 and CA1).
As shown in Fig. 4, the size of granule cells was determined by
measuring across the widest area of cytoplasma (largest possible
diameter), usually between the two visible poles of the cell. A
similar method has been published elsewhere [33]. For each
human subject, we measured at least 60 pS6-positive and -negative
cells in 5 different fields of DG. For each KA mouse, we selected 6
circular areas (75 mm diameter) in the upper and lower blades of
DG, and measured the size of each type of cells within the circular
area. Each circular area contains a center of pS6 negative neurons
which were surrounded with pS6/NeuN double-labeled neurons.
Student’s t test was used for statistical analysis. The data are
presented as mean 6 SD.
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To determine the distribution of mTOR activation at
different stages of hippocampal lesions, three time points were
chosen including 6 hours (the first stage), 5 days (the second
stage) and 5 weeks (the third stage) after kainate-induced
seizures, which were mainly accompanied by histopathological
changes including neuronal death, astrogliosis and granule cell
dispersion, respectively.
Firstly, immunohistochemistry assays were performed on mouse
brain sections 6 hours after seizure onset. Control hippocampus
(n=4) displayed widespread pS6 immunoreactivity (IR) in neurons
of dentate gyrus, CA1 and CA3 (Fig. 1A, B, C). After unilateral
intrahippocampal injection of 200 ng KA, mice experienced at
least 2 h of convulsive SE, and significantly increased pS6 IR was
observed in the dentate gyrus and CA3 regions at 6 h (n=4,
Fig. 1D, E). Extensive neuronal loss in CA1 was indicated by
pyknosis and pS6 IR was no longer present in this region (Fig. 1F).
In addition, increased pS6 IR was detected in the molecular layer
of dentate gyrus (which contains the dendrites of granule cells)
(Fig. 1D). Colocalization analysis indicated that pS6 was expressed
in NeuN-positive cells (Fig. 1, insets). Quantitative studies
confirmed the percentage increase (Fig. 1G).
Previously, pS6 expression levels have been reported to reach a
maximum on the fifth day [20]. This stage is characterized by
widespread astrogliosis (Fig. 2E). We examined pS6 IR 5 days after
KA injection, and found an increase primarily in reactive
astrocytes. In saline-injected control hippocampus (n=4), no
pS6 IR could be detected in glial cells (Fig. 2A–C, G). However, at
5 days post-SE, hippocampus both ipsilateral and contralateral to
the KA injection site displayed substantially upregulated pS6 IR in
the cytoplasm of reactive astrocytes (n=4), which was accompa-
nied by severe astrogliosis (Fig. 2H, I). Double immunofluores-
cence verified localization of pS6 in GFAP
-positive astrocytes in
area CA1 (Fig. 2D–F). Levels of pS6 IR in dentate gyrus of
ipsilateral (KA-injected) hippocampus were lower than their
previously elevated levels during the acute stage, and showed a
distribution similar to that observed in control hippocampus which
exhibited few neurons with apparent pS6 IR (Fig. 2G, H). In
Figure 1. Distribution of pS6 immunoreactivity (IR) in the hippocampus of control mice and 6 hours after induction of seizures. (A-C)
In saline-injected control mice (n=4), the density of pS6 IR varies in the different hippocampal subfields. In dentate gyrus (DG), pS6 IR is weak and
only present in some of granule cells (A). In the pyramidal cell layer, pS6 IR is detectable in the entire CA3 subfield (B) and strong in the CA1 region
(C). Hippocampus 6 hours post-SE (n=4) shows significantly increased pS6 IR within the dentate gyrus (D) and CA3 subfields (E) compared with
control hippocampus, but pS6 IR is absent in CA1 (F). Insets in D-F show increased expression of pS6 (GFAP-positive, red) in neurons (NeuN-positive,
green) of epileptic hippocampus than control hippocampus (A-C). Neuronal death is indicated by nuclear pyknosis. (G) Quantification of pS6 positive
neurons in hippocampus at 6 h after seizures (n=4) versus control mice (n=4). Error bars are means 6 SD., **P,0.01; ***P,0.001 is based on
Student’s t-test. ND, not detectable. ML: molecular layer; HS: hippocampal sclerosis; KA, kainic acid. Scale bar in A-F: 200 mm; in insets: 30 mm.
doi:10.1371/journal.pone.0039152.g001
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the entire dentate gyrus (Fig. 2I). Quantitative analysis revealed a
significant increase in both GFAP positive and GFAP/pS6 double-
positive astrocytes (Fig. 2K).
Granule cell dispersion is a common pathological feature of
patients with mTLE [34], and was reproduced in our mouse
model. It also represents the third stage of epileptogenesis.
Dispersion was observed at 2 weeks post-SE (n=4, Fig. 5A), and
at 5 weeks it was evident in the entire granular layer (n=5,
Fig. 5C). At 2 and 5 weeks post-SE, the mTOR pathway was
activated in dentate granule cells of hippocampus ipsilateral to KA
injection (Fig. 5A, C). In addition, pS6 IR in glial cell, while lower
Figure 2. Distribution of pS6 in the hippocampus of control mice and 5 days after induction of seizures. In CA1 of saline-injected
control mice (n=4), pS6 (green) is present in the cytoplasm of pyramidal neurons (A). Immunofluorescent staining of GFAP (red) shows distribution
and morphology of astrocytes under normal physiological conditions (B). There is no colocalization of pS6 and GFAP (C). During the latent phase,
increased pS6 expression is observed in the CA1 subfield of KA-injected hippocampus (n=4) (D), and colocalizes with GFAP, mostly in astrocyte-like
cells (arrows in F). Reactive gliosis is indicated by dramatically elevated GFAP (E). pS6 positive glia are present in hippocampus both ipsilateral (ipsi, H)
and contralateral (contr, I) to KA injection, although elevation of the former is more significant. Compared with saline-injected control hippocampus
(G), dentate gyrus of hippocampus ipsilateral to KA injection (H) contains fewer granule cells with strong pS6 IR (arrow in H), while almost no pS6
positive granule cells are present in the contralateral, non-injected hippocampus (I). (K) Quantification of GFAP positive and pS6/GFAP double
positive cells in CA1 subfield of KA-injected mice (n=4) versus control mice (n=4) at the second stage. Error bars are means 6 SD., **P,0.01;
***P,0.001 is based on Student’s t-test. Scale bar in A-F: 100 mm; in G-I: 200 mm.
doi:10.1371/journal.pone.0039152.g002
mTOR in Temporal Lobe Epilepsy
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higher than that in control hippocampus, and pS6-labeled glial
cells were located in the dispersed granular layer and both CA
regions (Arrows in Fig. 5A, C). The morphology of the
contralateral hippocampus was recovering from excitotoxic injury
at 2 and 5 weeks post-SE, and pS6 IR was no longer upregulated
(Fig. 5B, D).
Next, we asked whether the observed upregulated mTOR
pathway observed in the TLE mouse model also occurs in the
sclerotic hippocampus in patients with mTLE. Four non-sclerotic
hippocampus exhibited similar distributions of pS6 IR (non-HS
No. 2–4). Specifically, astrocyte-like cells with weak pS6 IR were
mostly restricted to the hilus (Fig. 3A), while pyramidal neurons in
CA1 and CA3 exhibited stronger pS6 IR (Fig. 3,c, d). All sclerotic
hippocampus displayed intense labeling for pS6 in reactive
astrocytes which were widespread in the dentate gyrus and both
CA subfields (Fig. 3B, e–h). Reactive astrocytes with upregulated
mTOR not only appeared in non-neuronal layers, but also
invaded the dispersed dentate gyrus (Fig. 3C). When compared
with the non-HS group, the number of pS6 IR astrocyte-like cells
in sclerotic hippocampus was remarkable increased in the
molecular layer of DG, in the hilus, in the CA1 and CA3 area,
respectively (Fig. 3E).
In the dentate gyrus of four non-HS cases (non-HS No. 2–4),
granule cells exhibited uniform cell size and pS6-positive cells
were hardly detected (Fig. 4A). The same was true of 11 of the
HS cases (HS patients No. 1–11 in Table 1). However, two HS
subjects did exhibit a large number of pS6 positive granule cells
(Fig. 4B; HS No. 12, 13). One non-HS hippocampus, resected
from a patient whose recently emerging seizures were triggered
by a glioma, also displayed many granule cells with strong pS6
IR (Fig. 4C; non-HS No.1). We reasoned that the granule cell
pS6 IR in the presence of the glioma could have resulted from
epileptic discharge, while mTOR activation in granule cells of
HS patients in the chronic stage of TLE may be related to
neuronal hypertrophy, a hallmark of this disease [35,36]. To test
this idea, we measured the cell size of pS6-positive and
surrounding pS6-negative neurons in the dentate gyrus of the
two HS and one non-HS (glioma) subjects with elevated pS6 IR.
Consistent with our prediction, the cell bodies of the pS6-positive
neurons in the two HS subjects were larger than neurons without
pS6 IR. However, no difference was found in the size of pS6-
positive and -negative granule cells in the non-HS (glioma)
subject (Fig. 4F). To reinforce the results, we used KA mice at 2
weeks to ensure whether the cell size is different in pS6 positive
versus pS6 negative neurons in the dispersed DG. As mentioned
Figure 3. pS6 expression in the sclerotic hippocampus (HS) and non-sclerotic controls (non-HS). Non-sclerotic hippocampus displays
weak pS6 IR in glial cells of the hilus (A), while in CA1 and CA3, staining is mainly observed in the cytoplasm of pyramidal cells, and only a few glia are
pS6-positive (a-d). In the sclerotic hippocampus, a large number of astrocytes (B) with significantly increased pS6 IR are observed in dentate gyrus
(DG) subfields including the hilus (B) and the molecular layer (e). Astrocytes with up-regulated pS6 invade the dispersed granular layer (C).
Immunofluorescence image shows colocalization of pS6 (green) with GFAP (red) in astrocytes surrounded by neurons (Inset in C). Glial proliferation
and strong pS6 IR are also detected in hilus, CA1 and CA3 of subjects with HS (f-h). (E) Quantification of astrocyte-like pS6 positive cells in CA1, CA3,
hilus and DG of HS (n=13) and non-HS (n=5). Error bars are means 6 SD., *P,0.05; **P,0.01 is based on Student’s t-test. Scale bar in A-B: 400 mm; in
C: 50 mm; in D: 20 mm. ML, molecular layer.
doi:10.1371/journal.pone.0039152.g003
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positive granule cells were surrounded by the NeuN (green)
positive neuronal cells at 2 weeks post-SE. Therefore, we selected
6 circular areas in the dentate gyrus of each section (n=4) which
contained both the upper and lower blades (as indicated in
Fig. 4D, E), and analyzed the cell size of pS6 positive and
negative neurons. The statistical analysis (Fig. 4F) confirmed that
mTOR activation in granule cells was accompanied by the
increase of cell body size.
Discussion
Abnormal intracellular signaling in refractory TLE is
receiving increasingly more attention and recent studies
implicate the mTOR pathway in this disease [15]. In this
study, we investigated the spatio-temporal distribution of
mTOR activation in an animal model of TLE and in sclerotic
hippocampus from patients with drug resistant mTLE. We
found that mTOR activation occurs in astrocytes and granule
cells in human sclerotic hippocampus, and different implications
are associated with each.
13/13 HS Patients Exhibited Widespread Reactive
Astrocytes with Overactivated mTOR
mTOR activation in the sclerotic hippocampus was most
prominent in reactive astrocytes. For obvious reasons, the sclerotic
hippocampus can be used to study only the chronic phase of
temporal lobe epileptogenesis. Animal models allow investigation
of mTOR activation at the two earlier stages of epilepsy [37].
Using a KA-induced TLE mouse model, we found that
upregulated mTOR in astrocytes first appeared at the second
stage and remained activated at 5 weeks post-SE.
Astrogliosis is a ubiquitous hallmark of all central nervous
system pathologies [38], and it has been reported that the mTOR
pathway is activated in reactive astrocytes in spinal cord injury
[25]. We observed similar mTOR activation in reactive astrocytes
of both TLE mice and patients with mTLE.
Previous research reported that mice with conditional deletion
of the tuberous sclerosis-1 (TSC-1) gene in astrocytes exhibit
abnormal glial proliferation and seizures [39]. Further, astrogliosis
can generate deficits in neuronal inhibition [8] and result in
reduced astrocytic uptake of potassium and glutamate [6,38].
Taken together, it raises the possibility that astrocytes with
overactivated mTOR could create a microenvironment conducive
to the temporal lobe epileptogenic process. Whether it is true
needs further study.
A recent study demonstrated that rapamycin treatment (which
inhibits mTOR) suppresses mossy fiber sprouting, but does not
affect seizure frequency [19]. However, rapamycin treatment has
other effects, including inhibition of GABAergic interneurons and
changes in synaptic complexity, and these could underlie its failure
to suppress seizures completely by blocking mTOR, as the study’s
authors discussed. Therefore, targeted inactivation of the mTOR
pathway in reactive astrocytes could potentially offer a promising
approach to obtain better inhibitory effects in TLE animal model.
2/13 HS Patients Displayed mTOR Activation in Granule
Cells
Granule cell hypertrophy is a common pathological feature in
HS [36]. We found that the mTOR pathway is activated in
Figure 4. mTOR activation in the granule cells of the sclerotic hippocampus is associated with neuronal hypertrophy. In the dentate
gyrus of non-sclerotic hippocampus, granule cells have uniformly sized cell bodies and pS6 expression is below detection level (A). In the sclerotic
hippocampus, pS6-positive and negative granule cells are different sizes (B, red and black two-headed arrows indicate pS6 negative and positive
neurons, respectively). pS6 positive granule cells in the dentate gyrus have larger cell bodies than do pS6-negative cells (F). A special non-sclerotic
hippocampus with recently emerging seizures induced by a glioma also exhibits some granule cells with substantially increased pS6 expression (C),
but both pS6-positive and -negative cells have the same cell size (F). KA mice at 2 weeks post-SE were used to study the cell size of pS6 positive and
negative neurons, both upper (D) and lower blades (E) of DG were involved in the statistic analysis (F). Error bars are means 6 SD., **p,0.01 is based
on Student’s t-test. Scale bar in A-C: 50 mm; in D-E: 25 mm.
doi:10.1371/journal.pone.0039152.g004
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as well as in the sclerotic hippocampus of two patients (HS patients
No. 12, 13). An in vitro study demonstrated that cell size was
controlled by mTOR [40]. Furthermore, increased cell body size
of granule cells in the neocortex of patients with TLE has been
reported in a previous study [33]. Our results indicated that
mTOR activation in granule cells of the sclerotic hippocampus
was associated with increased cell body size. The increased size of
neurons would yield more surface area for synaptic input [41], a
relative constancy in synaptic interval and space between adjacent
neurons appears to be important for the homeostasis of neural
circuits [42]. Although it has been reported that rapamycin
reduced hypertrophy nearly to control levels without affecting
seizure frequency in pilocarpine-treated mice [19], it remains open
to debate that the side effects of systemic administration of
rapamycin might confound the result.
Progressive mTOR activation in granule cells of TLE mice was
demonstrated by the increased number of involved granule cells
from the early to the late chronic phase (2 and 5 weeks post-SE,
respectively). However, only two HS patients exhibited pS6-
positive granule cells. We found that both of them had relatively
recent onset of TLE (4 and 9 years since their first seizure)
compared with most of the other patients studied, suggesting that
they were probably in an earlier period of the chronic phase. HS
patients No.1 and 2 also had relatively recent TLE yet showed no
mTOR activation in dentate granule cells, whether this is due to
the clinical heterogeneity require further study based on a larger
sample size.
Non-HS Cases as a Comparison Group
It is now increasingly recognized that abnormalities in cellular
signal transduction specific to the sclerotic hippocampus, rather
than alterations caused by epileptic discharges, underlie the
recurrent seizures seen in HS patients. Therefore, using non-HS
cases of TLE as a control group in this study was helpful for
determining whether the activated mTOR pathway is responsible
for the changes specific to HS. Furthermore, the duration of the
post mortem interval might be long enough to lose a substantial
proportion of phosphorylated proteins [43], so that non-HS tissues
are more suitable for comparison than autopsy tissues due to the
collection of both non-HS and HS groups were under the same
condition.
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Figure 5. pS6 IR in hippocampus 2 and 5 weeks after KA-induced seizures. (A) Dispersion of granule cells is visible at 2 weeks post-SE
ipsilateral (ipsi) to the KA injection (n=4), (C) and is pronounced at 5 weeks (n=5). pS6 is significantly upregulated in most of the dispersed granule
cells at 2 weeks (A), and in the entire dentate gyrus at 5 weeks (B). The morphology and pS6 IR in the corresponding non-injected (contralateral, conr)
hippocampus are normal (B, D). Immunofluorescence for pS6 (green) confirms the same observations. (Insets in C, D). Astrocyte-like cells with
increased pS6 IR are widespread in the dentate gyrus and CA area of sclerotic hippocampus (Arrows in A, C). Scale bar in A–B: 400 mm.
doi:10.1371/journal.pone.0039152.g005
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